| Source: |
| Type: |
| Also called CCND1 Gatekeeper of Cell-Cycle Commitment The main function of cyclin D1 is to maintain cell cycle and to promote cell proliferation. Cyclin D1 is a key regulatory protein involved in the cell cycle, particularly in the transition from the G1 phase to the S phase. It is part of the cyclin-dependent kinase (CDK) complex, where it binds to CDK4 or CDK6 to promote cell cycle progression. Cyclin D1 is crucial for the regulation of the cell cycle. Overexpression or dysregulation of cyclin D1 can lead to uncontrolled cell proliferation, a hallmark of cancer. Cyclin D1 is often found to be overexpressed in various cancers. Cyclin D1 can interact with tumor suppressor proteins, such as retinoblastoma (Rb). When cyclin D1 is overexpressed, it can lead to the phosphorylation and inactivation of Rb, releasing E2F transcription factors that promote the expression of genes required for DNA synthesis and cell cycle progression. Cyclin D1 is influenced by various signaling pathways, including the PI3K/Akt and MAPK pathways, which are often activated in cancer. In some cancers, high levels of cyclin D1 expression have been associated with poor prognosis, making it a potential biomarker for cancer progression and treatment response. |
| 6899- | FIS, | Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | 22Rv1 |
| 6902- | FIS, | Fisetin, a dietary flavonoid, induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cells |
| - | in-vitro, | Bladder, | T24/HTB-9 |
| 6994- | FIS, | Fisetin inhibits the activities of cyclin-dependent kinases leading to cell cycle arrest in HT-29 human colon cancer cells |
| - | in-vitro, | Colon, | HT29 |
| 6981- | Form, | Formononetin: a review of its source, pharmacology, drug combination, toxicity, derivatives, and drug delivery systems |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | PSA, | NA |
| 6982- | Form, | Formononetin: A Review of Its Anticancer Potentials and Mechanisms |
| - | Review, | Var, | NA |
| 6964- | Form, | Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo |
| - | vitro+vivo, | BC, | MCF7 |
| 6965- | Form, | Formononetin inhibits colon carcinoma cell growth and invasion by microRNA‑149‑mediated EphB3 downregulation and inhibition of PI3K/AKT and STAT3 signaling pathways |
| - | in-vitro, | CRC, | HCT116 |
| 7005- | Fuc, | Fucoidan and cancer: a multifunctional molecule with anti-tumor potential |
| - | Review, | Var, | NA |
| 1086- | GA, | Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation |
| - | in-vitro, | AML, | K562 |
| 1065- | GA, | Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression |
| - | vitro+vivo, | Pca, | NA |
| 7037- | GA, | Chit, | Gallic acid-loaded chitosan nanoparticles enhance the DNA damage and apoptotic features through inhibiting flap endonuclease-1 in triple-negative breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 7048- | GA, | Natural bioactive gallic acid shows potential anticancer effects by inhibiting the proliferation and invasiveness behavior in human embryonic carcinoma cells |
| - | in-vitro, | Var, | NA |
| 7029- | GA, | Gallic acid induces G1 phase arrest and apoptosis of triple-negative breast cancer cell MDA-MB-231 via p38 mitogen-activated protein kinase/p21/p27 axis |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | HS587T | - | in-vitro, | Nor, | MCF10 |
| 7059- | GamB, | Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells |
| - | in-vitro, | CRC, | HCT15 |
| 7067- | GamB, | Gambogic Acid and Its Role in Chronic Diseases |
| - | Review, | Var, | NA |
| 5150- | GamB, | Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-κB signaling pathway |
| - | in-vitro, | CLL, | KBM-5 | - | in-vitro, | Nor, | HEK293 |
| 7091- | GAR, | Garcinol-A Natural Histone Acetyltransferase Inhibitor and New Anti-Cancer Epigenetic Drug |
| - | Review, | Var, | NA |
| 7092- | GAR, | Garcinol and Its Role in Chronic Diseases |
| - | Review, | Var, | NA |
| 804- | GAR, | Garcinol inhibits the proliferation of endometrial cancer cells by inducing cell cycle arrest |
| - | in-vitro, | EC, | HEC1B | - | in-vitro, | EC, | ISH |
| 803- | GAR, | Induction of p21(Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 |
| 802- | GAR, | Garcinol acts as an antineoplastic agent in human gastric cancer by inhibiting the PI3K/AKT signaling pathway |
| - | in-vitro, | GC, | HGC27 |
| 801- | GAR, | Cisplatin, | Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers |
| - | in-vivo, | HNSCC, | NA |
| 798- | GAR, | Garcinol, an acetyltransferase inhibitor, suppresses proliferation of breast cancer cell line MCF-7 promoted by 17β-estradiol |
| - | in-vitro, | BC, | MCF7 |
| 826- | GAR, | Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo |
| - | vitro+vivo, | HCC, | HepG2 | - | vitro+vivo, | Liver, | HUH7 |
| 6570- | Ger, | Apoptosis-Mediated Anticancer Activity of Geraniol Inhibits NF-κB, MAPK, and JAK-STAT-3 Signaling Pathways in Human Thyroid Cancer Cells |
| - | in-vitro, | Thyroid, | TPC-1 |
| 7137- | GI, | 6-Shogaol from dried ginger inhibits growth of prostate cancer cells both in vitro and in vivo through inhibition of STAT3 and NF-κB signaling |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 | - | vitro+vivo, | Pca, | HMVP2 |
| 7136- | GI, | [6]-shogaol inhibits growth and induces apoptosis of non-small cell lung cancer cells by directly regulating Akt1/2 |
| - | vitro+vivo, | NSCLC, | H1650 |
| 7245- | Gink, | Ginkgetin inhibits the growth of DU-145 prostate cancer cells through inhibition of signal transducer and activator of transcription 3 activity |
| - | vitro+vivo, | Pca, | DU145 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | MCF10 |
| 7246- | Gink, | Biflavone Ginkgetin, a Novel Wnt Inhibitor, Suppresses the Growth of Medulloblastoma |
| - | in-vitro, | GC, | DAOY | - | in-vitro, | MB, | D283 |
| 7259- | Gink, | Ginkgetin induces apoptosis via activation of caspase and inhibition of survival genes in PC-3 prostate cancer cells |
| - | in-vitro, | Pca, | PC3 |
| 7284- | Gins, | 5-FU, | Ginsenoside Rg3 enhances the anticancer effect of 5-FU in colon cancer cells via the PI3K/AKT pathway |
| - | vitro+vivo, | CRC, | SW-620 | - | in-vitro, | CRC, | LoVo |
| 2438- | Gra, | Emerging therapeutic potential of graviola and its constituents in cancers |
| - | Review, | Var, | NA |
| 1232- | Gra, | Graviola: A Systematic Review on Its Anticancer Properties |
| - | Review, | NA, | NA |
| 7327- | GSE, | Dietary-feeding of grape seed extract prevents azoxymethane-induced colonic aberrant crypt foci formation in fischer 344 rats |
| - | in-vivo, | CRC, | NA |
| 30- | GSL, | A sesquiterpene lactone from Siegesbeckia glabrescens suppresses Hedgehog/Gli-mediated transcription in pancreatic cancer cells |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | AsPC-1 |
| 108- | GSL, | A sesquiterpene lactone from Siegesbeckia glabrescens suppresses Hedgehog/Gli-mediated transcription in pancreatic cancer cells |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | C3H10T1/2 |
| 7169- | HDN-1, | CHA, | Identification of epipolythiodioxopiperazines HDN-1 and chaetocin as novel inhibitor of heat shock protein 90 |
| - | in-vitro, | Lung, | H1975 | - | in-vitro, | Lung, | HCC827 | - | in-vitro, | Lung, | A549 |
| 7364- | HibSad, | Hibiscus sabdariffa calyx extract induces anti-proliferative and anti-migratory effects in ovarian cancer |
| - | in-vitro, | Ovarian, | OVCAR-3 |
| 7359- | HibSad, | Novel Insight into the Cellular and Molecular Signalling Pathways on Cancer Preventing Effects of Hibiscus sabdariffa: A Review - PubMed |
| - | Review, | Var, | NA |
| 7468- | HNK, | Honokiol and Its Emerging Role in Breast Cancer Therapy |
| - | Review, | BC, | NA |
| 2875- | HNK, | Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 | - | in-vitro, | SCC, | H226 |
| 2865- | HNK, | Liposomal Honokiol induces ROS-mediated apoptosis via regulation of ERK/p38-MAPK signaling and autophagic inhibition in human medulloblastoma |
| - | in-vitro, | MB, | DAOY | - | vitro+vivo, | NA, | NA |
| 2864- | HNK, | Honokiol: A Review of Its Anticancer Potential and Mechanisms |
| - | Review, | Var, | NA |
| 2891- | HNK, | Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs |
| - | Review, | Var, | NA |
| 2894- | HNK, | Pharmacological features, health benefits and clinical implications of honokiol |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | LoVo | - | in-vivo, | CRC, | HCT116 |
| 7542- | HT, | Hydroxytyrosol Induces Apoptosis and Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B | - | in-vitro, | Nor, | RWPE-1 |
| - | in-vitro, | BC, | SUM159 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | HS587T | - | in-vitro, | BC, | BT549 |
| 4639- | HT, | Hydroxytyrosol Induces Apoptosis, Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vitro, | BC, | SUM159 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:73 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid